Bristol-Myers Squibb Company (BMY) — Form 10-Q: Quarterly report

Bristol-Myers Squibb Company filed its quarterly report for the period ended September 30, 2026. The company reported no material changes to its critical accounting policies or market risk. During the three months ended September 30, 2026, the company acquired 105,063 shares of common stock surrendered to satisfy tax withholding obligations. The remaining share repurchase capacity under the program was $5.0 billion as of September 30, 2026.